Cytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.29491
Abstract: Immunotherapy has caused a paradigm shift in the treatment of several malignancies, particularly the blockade of programmed death‐1 (PD‐1) and its specific receptor/ligand PD‐L1 that have revolutionized the treatment of a variety of malignancies, but… read more here.
Keywords: combination agents; cytokines potential; treatment; cancer ... See more keywords
Abstract A093: Potential combination partners for a novel CDC7-selective Inhibitor, TAK-931
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-a093
Abstract: Background: Cell division cycle 7 (CDC7) is a serine/threonine kinase, which plays important roles in initiation of DNA replication. We developed a CDC7-selective inhibitor, TAK-931, designed to inhibit CDC7 activity in a time-dependent and ATP-competitive… read more here.
Keywords: potential combination; selective inhibitor; tak 931; combination ... See more keywords
PCSK9 and LRP6: potential combination targets to prevent and reduce atherosclerosis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Basic and Clinical Physiology and Pharmacology"
DOI: 10.1515/jbcpp-2021-0291
Abstract: Abstract Coronary artery disease (CAD) is a disease characterized by atherosclerosis formation which causes sudden cardiac death. The prevalence of CAD is expected to increase by 2030. Atherosclerosis started from accumulation of LDL in the… read more here.
Keywords: pcsk9 lrp6; potential combination; lrp6 potential; combination targets ... See more keywords